All In Biotech

Drug Trial Radar · NCT06705387

Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE

DeTECTS: Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE

Last checked: Nov 20, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Dec 23, 2024

Primary completion

Sep 2026

Study completion Mar 2027

Sponsor

Lead sponsor
University of Colorado, DenverAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
Nov 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to \[primary purpose: e.g., learn if intervention or health behavior can treat, prevent, diagnose etc.\] in \[describe participant population/primary condition; could include any of the following: sex/gender, age groups, healthy volunteers\]. The main question\[s\] it aims to answer \[is/are\]: Does dupilumab or swallowed topical fluticasone improve the diameter of the esophagus more? Does dupilumab or swallowed topical fluticasone reduce inflammation in the esophagus more? Are comparative effective clinical trials feasible in this patient population? Researchers will compare dupilumab 300 mg weekly compared to swallowed fluticasone to see if there is a difference in treatment response. Participants will be asked to: * Be randomized to either dupilumab sq weekly or swallowed topical fluticasone twice daily. * Participate in 8 study visits over 52 weeks * Complete questionnaires * Have an endoscopy with biopsies and EndoFLIP measurements. * Swallow an Esophageal String Test

Conditions

  • Eosinophilic Esophagitis

Interventions

  • DupilumabBiological

    Subcutaneous injection of 300mg per week for 16 weeks.

  • FluticasoneDrug

    Metered dose swallowed topical corticosteroid, given 1760mcg per day for 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Esophageal Lumen DistensibilityTime frame: From baseline endoscopy to the end of treatment at week 16.
  2. Reduction of epithelial eosinophilia to < 15 eos/hpf (binary)Time frame: This will be measured at week 16 end of treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Colorado/University of Colorado School of Medicine

    Aurora, Colorado · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.